CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
← catalyst calendarNCT07207811 · readout in 1,045 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,280estimated
Sites
295
Countries
Argentina, Australia, Belgium +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-02 | actual | When the study began enrolling |
| Primary completion | 2029-06-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions
- Drug: NNC6019-0001
- Drug: Placebo (NNC6019-0001)
Primary outcome
what the primary-completion date above is the date OFComposite Outcome of cardiovascular (CV) deaths and recurrent CV events (CV hospitalisations and urgent heart failure [HF] visits)
measured From baseline (week 0) to end of study (EOS) (up to approximately 4 years)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed